Postoperative Chemotherapy Use and Outcomes From ADAURA : Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC
-
Wu, Yi-Long (Guangdong Lung Cancer Institute)
;
John, Thomas (Austin Health) ;
Grohe, Christian (Evangelische Lungenklinik) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Goldman, Jonathan W. (University of California) ;
Kim, Sang-We (University of Ulsan) ;
Kato, Terufumi (Kanagawa Cancer Center) ;
Laktionov, Konstantin (Blokhin National Medical Research Center of Oncology) ;
Vu, Huu Vinh (Choray Hospital) ;
Wang, Zhije (Chinese Academy of Medical Sciences) ;
Lu, Shun (Shanghai Jiao Tong University) ;
Lee, Kye Young (Konkuk University Medical Center) ;
Akewanlop, Charuwan (Siriraj Hospital) ;
Yu, Chong-Jen (National Taiwan University College of Medicine) ;
de Marinis, Filippo (European Institute of Oncology) ;
Bonanno, Laura (Istituto Oncologico Veneto) ;
Domine, Manuel (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
Shepherd, Frances A. (University of Toronto) ;
Zeng, Lingmin (AstraZeneca) ;
Atasoy, Ajlan (AstraZeneca) ;
Herbst, Roy S. (Yale School of Medicine) ;
Tsuboi, Masahiro (National Cancer Center Hospital East) ;
Universitat Autònoma de Barcelona
visitant ::
identificació
Subscriure's to this discussion. You will then receive all new comments by email.
